H2S Donor, S-Propargyl-Cysteine, Increases CSE in SGC-7901 and Cancer-Induced Mice: Evidence for a Novel Anti-Cancer Effect of Endogenous H2S?
2011

H2S Donor S-Propargyl-Cysteine Shows Anti-Cancer Effects in Gastric Cancer

Sample size: 16 publication 10 minutes Evidence: moderate

Author Information

Author(s): MA Kaium, Liu Yan, Zhu Qing, Liu Chun-hua, Duan Jun-Li, Tan Benny K-H., Zhu Yi Zhun

Primary Institution: Fudan University, Shanghai, China

Hypothesis

Does S-propargyl-cysteine (SPRC) have an anti-cancer effect on gastric cancer cells and tumors?

Conclusion

The study found that SPRC has a significant anti-cancer effect on gastric cancer by inducing apoptosis and inhibiting tumor growth.

Supporting Evidence

  • SPRC treatment significantly decreased cell viability and suppressed the proliferation of gastric cancer cells.
  • SPRC induced apoptosis in cancer tissues and elevated expressions of p53 and Bax.
  • SPRC treatment increased CSE activity and H2S levels in both cell culture media and plasma of mice.

Takeaway

A special compound called SPRC can help fight stomach cancer by making cancer cells die and stopping them from growing.

Methodology

The study used both in vitro (cell culture) and in vivo (nude mice) experiments to assess the effects of SPRC on gastric cancer cells and tumors.

Limitations

The study was conducted on a specific type of cancer cells and animal models, which may not fully represent human gastric cancer.

Participant Demographics

Male nude mice were used for in vivo studies.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0020525

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication